Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by PET/CT

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified November 2005 by Université de Sherbrooke.
Recruitment status was:  Recruiting
Information provided by:
Université de Sherbrooke Identifier:
First received: November 17, 2005
Last updated: NA
Last verified: November 2005
History: No changes posted

Patients affected with non-Hodgkin’s large B-cell lymphoma are treated by chemotherapy. The evaluation of the response to this treatment is made by Positron Emission Tomography (PET/CT) in many centres where this technology is available. Presently PET scans and CT scans are being performed before treatment, after 4 cycles of chemotherapy and a few months after the end of treatment.

The goal of this study is to determine if it is possible to evaluate the efficiency of chemotherapy treatments after one cycle of treatment instead of waiting after 4 cycles, using a new scanner that combines PET and CT modalities. Data available from studies on these combined exams suggest that PET/CT helps to rapidly evaluate the response of the chemotherapy treatment. We also want to verify if some pathological characteristics measured from tumor cells will enable doctors to predict in advance the response to treatment.

Condition Intervention
Lymphoma, Large-Cell
Procedure: PET/CT 20 days after the first cycle of chemotherapy

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Early Evaluation of the Response of Large B Cell Non Hodgkin’s Lymphoma to Chemotherapy by Positron Emission Tomography Coupled With Computed Tomography (PET/CT)

Resource links provided by NLM:

Further study details as provided by Université de Sherbrooke:

Primary Outcome Measures:
  • Disease free survival at 2 years

Estimated Enrollment: 82
Study Start Date: November 2005
Estimated Study Completion Date: November 2009
Detailed Description:
Participation in this study involves 4 PET/CT exams, which occur before the treatments start, after the first cycle of chemotherapy, after 4 cycles of chemotherapy and then 12 weeks after the end of the treatments. The only additional test performed in this study compared to the regular follow-up of patients that are not in this study is the PET/CT exam after the first cycle. Your participation in this study will not affect treatment since the results of the first PET/CT test will not be communicated. All other tests results will be available in the medical record.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Newly diagnosed large B cells non Hodgkin’s lymphoma, CD20 positive
  • Chemotherapy treatments planned (R-CHOP) but not started

Exclusion Criteria:

  • Pregnancy (determined by urinary β-HCG and blood test)
  • Patients younger than 18 years
  • Unable to tolerate the procedure (30 minutes laying down on the back)
  • No chemotherapy treatment planned secondary to the patient's health performance
  • Previous lymphoma that has been treated with chemotherapy with the exception of stade I lymphoma treated only with radiotherapy.
  • All lymphoma other than large cell Non Hodgkin’s lymphoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00256490

Contact: Eric Turcotte, MD, FRCPC 819-346-1110 ext 11887
Contact: Chantal Langevin, inf 819-346-1110 ext 12887

Canada, Quebec
Centre Hospitalier Universitaire de Sherbrooke Recruiting
Sherbrooke, Quebec, Canada, J1H 5N4
Contact: Eric Turcotte, MD, FRCPC    819-346-1110 ext 11887   
Sponsors and Collaborators
Université de Sherbrooke
Principal Investigator: Eric Turcotte, MD, FRCPC Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Principal Investigator: Francois Bénard, MD, FRCPC Centre de recherche du Centre hospitalier universitaire de Sherbrooke
Principal Investigator: Virginie Bruneau, MD Centre de recherche du Centre hospitalier universitaire de Sherbrooke
  More Information Identifier: NCT00256490     History of Changes
Other Study ID Numbers: CRC 05-020
CIMF 2005-01
Study First Received: November 17, 2005
Last Updated: November 17, 2005

Keywords provided by Université de Sherbrooke:
Diffuse large B cells lymphoma

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases processed this record on May 25, 2017